- Poster presentation
- Open Access
The risk of materno-fetal infection. Importance of common laboratory tests
© Roşca et al; licensee BioMed Central Ltd. 2013
Published: 16 December 2013
Maternal infection is an important cause of morbidity and mortality in newborns. Rupture of membranes more than 18 hours before birth, fever during labor, urinary tract infections or vaginal infections (eg Streptococcus group B), treated or not treated during pregnancy or labor, may be cause of serious illness in the newborn. The aim of this study was to observe the evolution of infants exposed to certain risk factors, using the total blood count and the determination of C-reactive protein.
The authors have proposed a study on term babies born in our maternity “Prof. Dr. Panait Sârbu”, Bucharest, during 01 August 2012 – 01 August 2013, exposed to the following risk factors: rupture of membranes more than 18 hours before birth, vaginal infections treated or untreated during pregnancy, urinary infections, pregnant woman with fever during labor, using the total blood count and the value of C reactive protein.
All infants entered into the study were evaluated after at least 12 hours of life, determining the total blood count and C-reactive protein. There have been changes to these tests to a large number of subjects included in the study, and there have been cases in which, though the usual tests were within normal limits, infants developed symptoms, with no altered values of these laboratory tests (up to 72 hours). The infants exposed to certain risk factors (membranes ruptured more than 18 hours before birth and the presence of group B Streptococcus in maternal cultures, untreated antepartum) received prophylactic antibiotics at birth, however, registering changes in blood counts (leukocytosis/leukocytopenia) and/or increased levels of C-reactive protein in 10% of cases (resistance to antibiotics administered anterpartum/intrapartum?).
The result of common tests can be used to evaluate the newborn exposed to certain infectious factors, and to specify the correct therapeutic attitude, but in close relation with the clinical outcome, considering their non-specificity and potential false positive or negative results.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.